This is a pre-revenue clinical-stage biotech, the earnings miss vs consensus is secondary to upcoming catalysts. The key events to watch are the Phase 3 initiation and early Cohort C data from the ALLOHA trial, both expected in Q2 2026. Positive data could drive significant upside given the $73M market cap, while delays or negative readouts would pressure the stock. Cash burn of ~$24M/quarter provides ~5 quarters of runway.
TCRX drugs
TCRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 6 $1.25entry
- T+1 · 6mo ago −3.20%α −2.87% · $1.21
- T+5 · 6mo ago −8.00%α −9.13% · $1.15
- T+20 · 6mo ago −22.24%α −25.02% · $0.9720
- T+60 · 4mo ago −40.56%α −42.62% · $0.7430
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics reported Q1 2026 revenue of $1.0M (down 55% YoY from $2.2M) and a net loss of $28.7M ($-0.22 EPS), slightly better than the $-0.26 EPS in Q1 2025 but a miss vs the $-0.17 consensus estimate. The company reiterated upcoming catalysts including Phase 3 initiation for TSC-101 and early Cohort C data in Q2 2026, while cash burn continues with $128.1M remaining, funding operations into H2 2027.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $1.0M vs $2.2M YoY, down 55% due to Amgen collaboration timing
- Net loss $28.7M ($-0.22 EPS) vs $34.1M ($-0.26 EPS) in Q1 2025
- EPS of $-0.22 missed consensus estimate of $-0.17
- Cash and equivalents $128.1M at March 31, 2026, down from $152.4M at year-end 2025
- Cash runway into H2 2027 unchanged from prior guidance
- Phase 3 study of TSC-101 (ALLOHA-2) planned for Q2 2026
- Early Cohort C data from ALLOHA Phase 1 trial expected in Q2 2026
- Phase 1 study of TSC-102-A01/A03 targeting CD45 planned for H2 2026
- Pro forma shares outstanding flat at ~129.9M
Financial Impact
Revenue decline of $1.2M YoY (55%) driven by Amgen collaboration timing; net loss improved by $5.4M YoY due to lower R&D spend
Risk Factors
- Clinical trial failure or delay for TSC-101 Phase 3 or TSC-102 Phase 1
- Revenue concentration on single Amgen collaboration agreement
- Cash burn rate may require additional financing before H2 2027
- Pre-funded warrant dilution overhang (~70M warrants at $0.0001/share)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-207549 |
| Document: tcrx-20260506.htm | 0001193125-26-207549 |
| Document: 0001193125-26-207549-index-headers.html | 0001193125-26-207549 |
| Document: 0001193125-26-207549-index.html | 0001193125-26-207549 |
| Document: 0001193125-26-207549.txt | 0001193125-26-207549 |
| 8-K Data (Synthetic) | 0001193125-26-207549 |
Track record
15 reports on TCRX
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers